

## **BioNova Pharmaceuticals Announces Strategic Collaboration with Ardeagen Corporation to Co-develop Antibody Drug Conjugate Therapies for Patients with Cancer**

Shanghai, China, February 22, 2021 – **BioNova Pharmaceuticals Limited (BioNova)**, a company dedicated to the discovery, development and commercialization of innovative medicines for the treatment of diseases with unmet medical needs, today announced a global strategic collaboration with **Ardeagen Corporation (Ardeagen)**, a company focused on discovery and development of Antibody Drug Conjugates (ADCs), for the discovery, development and commercialization of up to three ADCs for the treatment of oncology/hematology malignancies.

“We are very excited about this opportunity to work with Ardeagen colleagues to accelerate the discovery and development of multiple potential best-in-class or first-in-class ADCs,” said Bryan Huang, CFO and Chief Strategy Officer of BioNova, “Ardeagen’s team has extensive experience with a variety of in-depth ADC technologies, and have been instrumental in bringing several ADCs to the market, including Adcetris and Trodelvy. We believe this collaboration will be highly synergistic and create significant value for the stakeholders and patients.”

“We believe BioNova is an ideal partner for Ardeagen”, said Dr. Morris Rosenberg, CEO and Founder of Ardeagen. “Their combination of strategic vision, extensive clinical development expertise and strong financial resources will significantly accelerate the development of our pipeline programs.”

Under the collaboration, BioNova and Ardeagen will form a joint team to develop and commercialize up to three ADCs in the oncology area on a global basis. Ardeagen will lead the research and discovery activities up to IND filing. Ardeagen will also lead the manufacturing and global drug supply for clinical development and commercialization. BioNova will lead the translational, clinical development and global new drug registration. The companies will co-develop and share all future costs and profits.

### **About BioNova**

BioNova Pharmaceuticals Limited is a privately held clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative medicines for cancer and other life-threatening diseases with high unmet medical needs. Headquartered in Shanghai, BioNova is a fast-growing company of which robust pipeline is built upon internal R&D programs, collaborations with and acquisitions from partners of cutting-edge technology. With a highly capable and experienced team in combination with substantial funding, BioNova is committed to delivering high-quality innovative medicines to patients in China and globally.

### **About Ardeagen**

Ardeagen Corporation is a privately held US-based biotechnology company focused on the discovery and development of Antibody Drug Conjugate (ADC) therapies for the treatment of cancer.

### **BioNova Contact:**

Email: [info@bionovapharma.com](mailto:info@bionovapharma.com)